Rocket Pharmaceuticals (RCKT) Interest & Investment Income (2015 - 2026)

Rocket Pharmaceuticals has disclosed Interest & Investment Income across 12 years of filings, most recently posting $161000.0 for Q1 2026.

• Interest & Investment Income for Q1 2026 came in at $161000.0, down 87.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 million (down 68.92% YoY), and the FY2025 annual result was $3.2 million, down 61.07% from the prior year.
• Interest & Investment Income came in at $161000.0 for Q1 2026 at Rocket Pharmaceuticals, down from $690000.0 in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $3.0 million in Q1 2024 to a low of $161000.0 in Q1 2026.
• The 5-year median for Interest & Investment Income is $1.2 million (2022), against an average of $1.2 million.
• Across the five-year window, Interest & Investment Income surged 206.26% in 2023 and slumped 87.95% in 2026, its largest moves.
• Rocket Pharmaceuticals' Interest & Investment Income stood at $1.2 million in 2022, then sank by 34.62% to $814000.0 in 2023, then soared by 98.65% to $1.6 million in 2024, then tumbled by 57.33% to $690000.0 in 2025, then plunged by 76.67% to $161000.0 in 2026.
• The last three Interest & Investment Income figures came in at $161000.0 (Q1 2026), $690000.0 (Q4 2025), and $709000.0 (Q3 2025), per Business Quant data.